Results from four studies within a major Roche-run clinical trials program of an investigational gut disease drug have muddled the antibody’s path forward after its performance proved mixed.
The company has been studying etrolizumab, an antibody designed to block two members of a family of proteins called integrins, as a potential treatment for the two most common inflammatory bowel diseases. The aim of the investigational dual anti-integrin, which patients administer monthly via an injection, is to stop white blood cells from entering the gut and reduce the inflammatory effects caused by the immune overreaction that characterizes IBD.
Ulcerative colitis (UC) is… Read more »
UNDERWRITERS AND PARTNERS
